SlidesetHIVRussian HIV Clinical Forum 2019Integrase Inhibitors in ART Regimens in Patients with Co-Infection - A.V. Kravchenko, DMCView Slideset
EOElena Orlova-MorozovaMD, PhDSlidesetHIVRussian HIV Clinical Forum 2019Integrase Inhibitors as a Component of Comprehensive Care... - Elena Orlova-Morozova, MD, PhDView Slideset
ASAnca Streinu-CercelMD, PhDSlidesetHIVRussian HIV Clinical Forum 2019Clinical Utility of INSTI in Women - Anca Streinu-Cercel, MD, PhDView Slideset
SlidesetHIVRussian HIV Clinical Forum 2019Clinical Criteria for Choosing an ART Regimen - O.G. YurinView Slideset
AKAlina KirichenkoMDSlidesetHIVRussian HIV Clinical Forum 2019Circulating HIV-1 and LN Subtypes to Integrase Inhibitors in the Russia - Alina KirichenkoView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2018Pharmacologic characteristics and delivery options for integrase inhibitors- Courtney Fletcher, PharmDView Slideset
LWLaura WatersMD, FRCPSlidesetHIVEuropean HIV Clinical Forum 2018Long-acting ARV for treatment & prevention: clinical considerations- Laura Waters, MD, FRCPView Slideset
SWSharon WalmsleyCM, MD, FRCPCSlidesetHIVEuropean HIV Clinical Forum 2018Integrase inhibitors in specific populations- Women and those aging with HIV- Sharon Walmsley, FRCPC, MD, MSCView Slideset
SlidesetHIVEuropean HIV Clinical Forum 2018Longer duration of virological suppression and a fully active companion drug ensure a high rate of virological control in HIV-1 infected patients switching to a dual therapy containing integrase inhibitors- Daniele ArmeniaView Slideset
PCPedro CahnMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2018Switching antiretroviral therapy to safer strategies based on intergrase inhibitors- Pedro Cahn, MD, PhDView Slideset
JAJose ArribasMDSlidesetHIVEuropean HIV Clinical Forum 2018Reduced drug regimens- What are the data?- Jose Arribas, MDView Slideset
RPRoger ParedesMD, PhDSlidesetHIVEuropean HIV Clinical Forum 2018Resistance to integrase inhibitors- What clinicians need to know- Roger Paredes, MD, PhDView Slideset
